These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 26188238)

  • 41. Hepatic artery chemoinfusion with chemoembolization for neuroendocrine cancer with progressive hepatic metastases despite octreotide therapy.
    Christante D; Pommier S; Givi B; Pommier R
    Surgery; 2008 Dec; 144(6):885-93; discussion 893-4. PubMed ID: 19040993
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The presence of somatostatin receptors in malignant neuroendocrine tumor tissue predicts responsiveness to octreotide.
    Kvols LK; Reubi JC; Horisberger U; Moertel CG; Rubin J; Charboneau JW
    Yale J Biol Med; 1992; 65(5):505-18; discussion 531-6. PubMed ID: 1364090
    [TBL] [Abstract][Full Text] [Related]  

  • 43. New Treatments for the Carcinoid Syndrome.
    Loughrey PB; Zhang D; Heaney AP
    Endocrinol Metab Clin North Am; 2018 Sep; 47(3):557-576. PubMed ID: 30098716
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Treatment of carcinoid syndrome with a somatostatin analogue].
    Döbrönte Z; Stöckert A; Végh G; Varga L
    Orv Hetil; 1992 Mar; 133(12):731-4. PubMed ID: 1372969
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A single-centre experience with octreotide in the treatment of different hypersecretory syndromes in patients with functional gastroenteropancreatic neuroendocrine tumors.
    Berković MC; Altabas V; Herman D; Hrabar D; Goldoni V; Vizner B; Zjacić-Rotkvić V
    Coll Antropol; 2007 Jun; 31(2):531-4. PubMed ID: 17847934
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Successful treatment of carcinoid syndrome in two cases of bronchial carcinoid].
    Katakami N; Matsumoto H; Ishihara K; Umeda B
    Nihon Kyobu Shikkan Gakkai Zasshi; 1995 Nov; 33(11):1313-8. PubMed ID: 8583728
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The carcinoid syndrome: palliation by hepatic artery embolization.
    Carrasco CH; Charnsangavej C; Ajani J; Samaan NA; Richli W; Wallace S
    AJR Am J Roentgenol; 1986 Jul; 147(1):149-54. PubMed ID: 2424291
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Use of a somatostatin analogue in association with surgery and hepatic arterial embolisation in the treatment of the carcinoid syndrome.
    Ahlman H; Ahlund L; Dahlström A; Nilsson O; Skolnik G; Tisell LE; Tylén U
    Br J Cancer; 1987 Dec; 56(6):840-2. PubMed ID: 2893640
    [No Abstract]   [Full Text] [Related]  

  • 49. Prolonged life-threatening hypoglycaemia following dose escalation of octreotide LAR in a patient with malignant polysecreting pancreatic neuroendocrine tumour.
    Abell SK; Teng J; Dowling A; Hofman MS; MacIsaac RJ; Sachithanandan N
    Endocrinol Diabetes Metab Case Rep; 2015; 2015():140097. PubMed ID: 25755880
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Metformin with everolimus and octreotide in pancreatic neuroendocrine tumor patients with diabetes.
    Pusceddu S; Buzzoni R; Vernieri C; Concas L; Marceglia S; Giacomelli L; Milione M; Leuzzi L; Femia D; Formisano B; Mazzaferro V; de Braud F
    Future Oncol; 2016 May; 12(10):1251-60. PubMed ID: 26890290
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumors.
    Eriksson BK; Larsson EG; Skogseid BM; Löfberg AM; Lörelius LE; Oberg KE
    Cancer; 1998 Dec; 83(11):2293-301. PubMed ID: 9840528
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Different response to the long-acting somatostatin analogues lanreotide and octreotide in a patient with a malignant carcinoid.
    Raderer M; Kurtaran A; Scheithauer W; Fiebiger W; Weinlaender G; Oberhuber G
    Oncology; 2001; 60(2):141-5. PubMed ID: 11244329
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical review 23: The use of the long-acting somatostatin analog octreotide in the treatment of gut neuroendocrine tumors.
    Wynick D; Bloom SR
    J Clin Endocrinol Metab; 1991 Jul; 73(1):1-3. PubMed ID: 1646213
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A patient with a metastatic gastroenteropancreatic endocrine carcinoma causing hyperinsulinaemic hypoglycaemia and the carcinoid syndrome.
    Hinchliffe E; Allcock RL; Mansoor W; Myers MA
    Ann Clin Biochem; 2011 Nov; 48(Pt 6):579-83. PubMed ID: 21948491
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues.
    Wolin EM; Jarzab B; Eriksson B; Walter T; Toumpanakis C; Morse MA; Tomassetti P; Weber MM; Fogelman DR; Ramage J; Poon D; Gadbaw B; Li J; Pasieka JL; Mahamat A; Swahn F; Newell-Price J; Mansoor W; Öberg K
    Drug Des Devel Ther; 2015; 9():5075-86. PubMed ID: 26366058
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Orthotopic liver transplantation for carcinoid tumour metastatic to the liver: anesthetic management.
    Claure RE; Drover DD; Haddow GR; Esquivel CO; Angst MS
    Can J Anaesth; 2000 Apr; 47(4):334-7. PubMed ID: 10764178
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Improved control of severe hypoglycemia in patients with malignant insulinomas by peptide receptor radionuclide therapy.
    van Schaik E; van Vliet EI; Feelders RA; Krenning EP; Khan S; Kamp K; Valkema R; van Nederveen FH; Teunissen JJ; Kwekkeboom DJ; de Herder WW
    J Clin Endocrinol Metab; 2011 Nov; 96(11):3381-9. PubMed ID: 21917872
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Use of octreotide in the treatment of digestive neuroendocrine tumours. Seven year experience in 20 cases including 9 cases of metastatic midgut carcinoid and 5 cases of metastatic gastrinoma.
    Fiasse R; Pauwels S; Rahier J; Jamar F; Ketelslegers JM; Hassoun A; de Longueville M
    Acta Gastroenterol Belg; 1993; 56(3-4):279-91. PubMed ID: 8266771
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combination with alpha-interferon.
    Janson ET; Oberg K
    Acta Oncol; 1993; 32(2):225-9. PubMed ID: 7686765
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Octreotide long-acting repeatable among elderly patients with neuroendocrine tumors: a survival analysis of SEER-Medicare data.
    Shen C; Shih YC; Xu Y; Yao JC
    Cancer Epidemiol Biomarkers Prev; 2015 Nov; 24(11):1656-65. PubMed ID: 26315553
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.